Our study suggests thatthe mPFS and mOS for EGFR-TKI therapy is different between different sampletypes, and the prognosis of the tissue sample delivery population is significantlybetter than that of the liquid biopsy and pleural effusion cytology deliverypopulations. This evidence concerns the gene EGFR and Pleural effusion.